surgery. TEI Med actually licensed technology from TEI Bio for
wound healing and orthopedics.
“This acquisition broadens our presence in regenerative
wound care and tissue repair and represents a significant push
forward toward our growth objectives for 2015 and beyond. The
addition of TEI is an important, strategic next step for both our
channel and international expansion priorities. We are enthusiastic about both TEI’s product development and commercial expertise, which accelerates our ability to establish an immediate presence in the diabetic foot ulcer space,” Arduini said in a company
release announcing the deal.
According to Integra, a number of factors made the purchase
particularly attractive. Most notable was TEI’s PriMatrix Dermal
Repair Scaffold, which enhanced Integra’s offering in the regenerative would care and tissue repair space. The firm generated
2014 revenues of $63.5 million.
“It is an exciting time for TEI, and I am confident in Integra’s
ability to grow our leading platform technology to drive broader
expansion into regenerative medicine including wound care,
plastic and reconstructive surgery, and other soft tissue repair
and reconstruction applications,” Dr. Yiannis Monovoukas,
Ph.D., chairman, president, and CEO of TEI, added in the same
The TEI transaction was just the largest of a number of acquisitions Integra made in 2015. The company kicked off the year in
January with the announcement that it had acquired Metasurg’s
foot and ankle product portfolio in the month prior. The buy enhanced Integra’s lower extremity product offering while also providing the opportunity to distribute a biologic allograft derived
from human placental tissue as a compliment to the company’s
wound care offerings. Posting revenues of approximately $6 million, Integra expects the product line to return to double-digit
growth numbers following the transition period.
In September, the company announced the purchase of two
product portfolios from Tornier. The Salto Talaris and Salto XT
ankle replacement products, as well as the Futura silastic toe
replacement products were purchased for $6 million in a cash
transaction. Integra cited interest in the products as an opportunity to both enhance its lower extremities product offering and
accelerate entry into the U.S. total ankle replacement market.
Lastly, in December, the company acquired the assets of Tek-med Instruments, an Italian distributor of Integra products within
the country. The deal, worth $14.2 million, provided support to
the growth of the Specialty Surgical Solutions segment within
Italy. In addition, with Tekmed’s focus on neurosurgery and neu-rotrauma, the deal also enhanced the offerings for those areas.